ARIA: A Phase 1b/2, Open-label, Multi Cohort Trial of Tazemetostat in Combination With Various Treatments in Subjects With Relapsed or Refractory Hematologic Malignancies

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Hyaluronidase (Primary) ; Lenalidomide (Primary) ; Mosunetuzumab (Primary) ; Pomalidomide (Primary) ; Tafasitamab (Primary) ; Tazemetostat (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms ARIA
Sponsors Epizyme

11 Aug 2023 Planned End Date changed from 1 May 2028 to 5 Jul 2023.
11 Aug 2023 Planned primary completion date changed from 1 Dec 2027 to 5 Jul 2023.
11 Aug 2023 Status changed from recruiting to withdrawn prior to enrolment.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com